Search - tctmd.com

Displaying 41 - 60 of 113

Sort: Relevancy | Date

News Daily News

TAVR Without Balloon Aortic Valvuloplasty: Increasingly Common, With Similar Outcomes

Yael L. Maxwell

September 17, 2018

News Conference News ESC 2018

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

Yael L. Maxwell

September 06, 2018

News Conference News ESC 2018

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Todd Neale

August 28, 2018

News Conference News ESC 2018

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

Michael O'Riordan

August 28, 2018

News Conference News EuroPCR 2018

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

Caitlin E. Cox

May 25, 2018

News Conference News EuroPCR 2018

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Michael O'Riordan

May 25, 2018

News Conference News EuroPCR 2018

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Caitlin E. Cox

May 23, 2018

Presentation TCT 2017

Case #10: Calcified Distal LMCA Lesion Managed With OCT-Guided Predilatation

Presenter: Evald H. Christiansen, Simon J. Walsh, Stuart Watkins

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Todd Neale

October 30, 2017

News Conference News TCT 2017

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Yael L. Maxwell

October 30, 2017

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

L.A. McKeown

September 18, 2017

News Daily News

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

L.A. McKeown

August 03, 2017

News Conference News EuroPCR 2017

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

Michael O'Riordan

May 19, 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS in China, Japan

News Conference News EuroPCR 2017

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Michael O'Riordan

May 17, 2017

News Daily News

Absorb BVS Use Restricted in Europe

Michael O'Riordan

April 06, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

Advertisement

TAVR Without Balloon Aortic Valvuloplasty: Increasingly Common, With Similar Outcomes

TAVR Debris Captured by Sentinel Embolic Protection Differs by Valve Type

BASKET-SMALL 2: Drug-Coated Balloon Fares Well Against DES for De Novo Small-Vessel Disease

Too Little, Too Late? Absorb BVS Shows Promising Results in STEMI Patients

DCBs for CAD in Certain Patients With Large Vessel De Novo Disease? DEBUT Says Yes

New Bioresorbable Scaffold, Magmaris, Delivers Positive Early Outcomes

Embolic Protection in TAVR: Signs of Benefit, but Road Map for Use Still Uncharted

Case #10: Calcified Distal LMCA Lesion Managed With OCT-Guided Predilatation

Long-term Absorb BVS Data Continue to Disappoint

DARE Supports Drug-Coated Balloon as Alternative to DES for Any In-Stent Restenosis

Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

Registry Confirms Long-term Durability of Drug-Coated Balloon for Femoropopliteal Lesions

Scaffold Thrombosis ‘Unpredictable’ With Absorb: AIDA Analysis

No Very Late Scaffold Thrombosis Risk With Absorb BVS Studies in China, Japan

Absorb BVS Use Restricted in Europe

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content